Michael J. LaBarre , Ph.D., Vice President, Chief Scientific Officer

Dr. Michael J. LaBarre has been with Halozyme since 2008 and oversees the research and development of early pipeline assets, product development, and Halozyme’s ENHANZE platform partnerships. Dr. LaBarre brings strong expertise in chemistry, manufacturing and controls (CMC) along with over 23-years of experience across all aspects of biopharmaceutical research and development. In his previous role as Vice President of Product Development at Paramount BioSciences, LLC, Dr. LaBarre led the CMC efforts for all of the product development programs within Paramount’s portfolio companies. Prior to joining Paramount, Dr. LaBarre served in various research and development positions from 1995 to 2006 at Biogen Idec (IDEC from 1995 to 2004), where he had responsibility for analytical and formulation development, protein purification, and physicochemical/biochemical characterization supporting numerous IND and BLA submissions, including those for the commercial products RITUXAN® and ZEVALIN®. His last position with Biogen Idec was Director of Analytical and Protein Biochemistry within the Discovery Research group. Prior to IDEC, Dr. LaBarre spent two years at Vical, Inc. in the analytical methods development group and he began his career at Hybritech in San Diego, where he held positions in regulatory affairs and manufacturing technical support, focusing on conjugated/radiolabeled antibody technologies and analytical chemistry. Dr. LaBarre received his B.S. in chemistry from Southampton College of Long Island University and his Ph.D. in bioinorganic chemistry from the University of Arizona.


You are now leaving Halozyme.com. Halozyme is not responsible for or endorses the content of the linked site.